We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“GLP-1RA's favourable VTE [venous thromboembolism] profile among patients with AF/AFL [atrial flutter] and T2DM [T2D] suggests that GLP-1RAs may confer vascular benefits and could be considered when selecting glucose-lowering therapy in this high-risk population. Importantly, these findings do not alter the established role of OAC [oral anticoagulant] for the prevention of AF-related stroke and systemic embolism,”
No takes yet. Share an insight, caveat, or question.
Lo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: